Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,123.38 +497.85 (+0.78%) CMC Crypto 200
1,379.68 +67.06 (+5.11%)
Alkermes plc (ALKS)
| Previous close | 23.76 |
| Open | 23.65 |
| Bid | 23.61 x 100 |
| Ask | 23.64 x 100 |
| Day's range | 23.48 - 23.80 |
| 52-week range | 22.01 - 33.71 |
| Volume | |
| Avg. volume | 1,969,019 |
| Market cap | 3.997B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 7.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2024
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.
- PR Newswire
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Te
- PR Newswire
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI® (olanzapine and samidorphan) in patients who received up to four years of treatment. LYBALVI is approved in the U.S. for the
